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Abstract
Background: Fecal leukocyte test (FLT) is widely used to screen for invasive diarrheas including
C. difficile associated diarrhea (CDAD), which account for more than 25 % of all antibiotic
associated diarrhea.
Method: 263 stool samples from patients with suspected CDAD were studied simultaneously for
fecal leukocyte test (FLT) and Clostridium difficile toxin assay (CDTA). FLT was performed by the
Giemsa technique and CDTA was performed by enzyme immuno assay (EIA).
Results: Sensitivity, specificity, positive predictive value and negative predictive value of FLT as
compared to CDTA were 30%, 74.9%, 13.2% and 89.3% respectively.
Conclusion: Considering the poor sensitivity of FLT, and the comparable cost and time of
obtaining a CDTA at our institution, we conclude that FLT is not a good screening test for CDAD.
Possible reasons for FLT being a poor predictor of CDTA are discussed.
Introduction
Willmore and Shearman[1] first described the fecal leuko-
cyte stain in 1918 followed by its clinical use for diagnosis
of bacterial diarrhea in 1972 by Harris et al [2]. Today
fecal leukocyte testing (FLT) is widely used to screen for
inflammatory diarrhea including C. difficile diarrhea,
which account for more than 25 % of all antibiotic asso-
ciated diarrhea. Laboratory diagnosis of C. difficile associ-
ated diarrhea (CDAD) is based on the detection of C.
difficile toxins in stool samples by a cell culture cytotoxic-
ity assay or enzyme immunoassay. We evaluated FLT
within an inpatient cohort, defining the test's sensitivity,
specificity, positive predictive value (PPV) and negative
predictive value (NPV) for patients with CDAD.
Materials and methods
After obtaining approval from the institutional review
board at Louisiana State University Health Sciences
Center, Shreveport, a retrospective review of laboratory
data was done on 263 inpatients whose stool samples
were simultaneously submitted for FLT and C. difficile
toxin assay (CDTA). Specimens were submitted between
January 2001 and June 2004.
FLT was performed on fresh stool specimens. Samples are
obtained in a clean dry container. Stool specimens are
applied as a thin smear on a slide using a cotton swab.
After the slides are air dried, they are smeared with Wright
stain and examined under the microscope for white blood
cells (WBC). Criteria for positive FLT are > 1 WBC/high
power field. The cost of obtaining a FLT is about $30.
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Time of availability of the test is approximately one hour
after submission of the stool specimen. Specimens were
processed in the same laboratory, but likely by different
technicians.
CDTA was done using Premier™ Toxins A&B (PT A&B). PT
A&B is an EIA for the direct detection of C.difficile toxin A
and toxin B. CDAD was defined as diarrhea with a positive
CDTA. The cost of obtaining CDTA is about $30. Time of
availability is approximately 45 minutes after submission
of the specimen.
Results
Of the 263 stool samples tested at the same time for FLT
and CDTA, 68 were positive for FLT and 30 were positive
for CDTA (Table 1). The sensitivity and specificity of FLT
as compared to CDTA was 30 % and 74.9 % respectively.
The PPV and NPV of FLT was 13.2 % and 89.3 % respec-
tively for CDTA. 70% of all stool specimens positive for
CDTA had a negative FLT. Prevalence of a positive CDTA
was 11.4%.
Discussion
Clostridium difficile (C.difficile) is the commonest cause
of nosocomial diarrhea associated with significant mor-
bidity and health care costs.[3,4]. Despite being perceived
as a common cause of antibiotic associated diarrhea,
C.difficile associated diarrhea (CDAD) is often difficult to
diagnose.[3] Enzyme immunoassay (EIA) against C.diffi-
cile toxin A and/or toxin B in stool specimens is currently
the acceptable method of diagnosing C.difficile diarrhea.
[5-7] Since C.difficile is considered to be a type of invasive
diarrhea, fecal leukocyte test (FLT), that has been pro-
posed by Harris et al [2] as a rapid test to differentiate
invasive versus non-invasive diarrhea [2,8] might be use-
ful as a predictor of C.difficile diarrhea.
There is conflicting evidence regarding the use of FLT as a
screening test for CDAD. While the studies done by Savola
et al [9], Mark et al [10], Manabe et al [11] and
Shanholtzer et al [12] concluded FLT as a poor predictor
of CDAD; studies done by Bartlett et al [13] and Fekety et
al [14] proposed that FLT might be a useful predictor in
CDAD. The results of our study reinforce the fact that FLT
is a poor predictor of CDAD; because 70% of stool speci-
mens positive for C. difficile toxin are negative for fecal
leukocyte. There is no significant time or cost savings by
obtaining a FLT, as opposed to CDTA in patients with sus-
pected CDAD.
Poor predictability of CDAD with a FLT can partially be
explained by inter-observer variability in interpreting fecal
leukocytes under microscopy. False negative results could
also be due to degeneration of fecal leukocytes secondary
to delay in processing stool specimens. This is reinforced
by the fact that objective tests to detect fecal leukocytes
like the fecal lactoferrin [15-18] or the fecal leukocyte este-
rase test [19] are better indicators of fecal leukocytes than
the FLT. Low PPV can also be explained by the fact that
EIA for toxin detection is less sensitive compared to the
neutralizing tissue culture cytotoxicity assay for CDAD.
Considering the poor sensitivity and comparable cost and
promptness with C.difficile toxins assay in our institution,
we conclude that FLT is not a good screening test for
CDAD in inpatients.
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